The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
VolitionRX Ltd (AMEX: VNRX) closed the day trading at $0.25 down -0.79% from the previous closing price of $0.25. In other words, the price has decreased by -$0.79 from its previous closing price. On the day, 0.68 million shares were traded. VNRX stock price reached its highest trading level at $0.2534 during the session, while it also had its lowest trading level at $0.2404.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on April 08, 2025, initiated with a Buy rating and assigned the stock a target price of $2.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when Reynolds Cameron John bought 20,000 shares for $0.35 per share. The transaction valued at 7,000 led to the insider holds 2,554,847 shares of the business.
Reynolds Cameron John bought 110,000 shares of VNRX for $56,100 on Oct 14 ’25. The President and CEO now owns 2,534,847 shares after completing the transaction at $0.51 per share. On Oct 14 ’25, another insider, Innes Guy Archibald, who serves as the Director of the company, bought 96,153 shares for $0.51 each. As a result, the insider paid 49,038 and bolstered with 1,062,967 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VNRX now has a Market Capitalization of 30700392 and an Enterprise Value of 40445132. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.88. Its current Enterprise Value per Revenue stands at 27.476 whereas that against EBITDA is -1.868.
Stock Price History:
The Beta on a monthly basis for VNRX is 1.22, which has changed by -0.60317457 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, VNRX has reached a high of $0.94, while it has fallen to a 52-week low of $0.23. The 50-Day Moving Average of the stock is -27.78%, while the 200-Day Moving Average is calculated to be -53.49%.
Shares Statistics:
Over the past 3-months, VNRX traded about 1.73M shares per day on average, while over the past 10 days, VNRX traded about 2651360 shares per day. A total of 109.62M shares are outstanding, with a floating share count of 97.40M. Insiders hold about 20.69% of the company’s shares, while institutions hold 21.27% stake in the company. Shares short for VNRX as of 1765756800 were 543884 with a Short Ratio of 0.31, compared to 1763078400 on 362805. Therefore, it implies a Short% of Shares Outstanding of 543884 and a Short% of Float of 0.58.
Earnings Estimates
A detailed examination of VolitionRX Ltd (VNRX) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.2 and -$0.24 for the fiscal current year, implying an average EPS of -$0.21. EPS for the following year is -$0.09, with 4.0 analysts recommending between $0.08 and -$0.15.
Revenue Estimates
6 analysts predict $714.08k in revenue for. The current quarter. It ranges from a high estimate of $868k to a low estimate of $560k. As of. The current estimate, VolitionRX Ltd’s year-ago sales were $191.66kFor the next quarter, 6 analysts are estimating revenue of $806.25k. There is a high estimate of $1.2M for the next quarter, whereas the lowest estimate is $600k.
A total of 5 analysts have provided revenue estimates for VNRX’s current fiscal year. The highest revenue estimate was $2.15M, while the lowest revenue estimate was $1.8M, resulting in an average revenue estimate of $1.95M. In the same quarter a year ago, actual revenue was $1.23MBased on 5 analysts’ estimates, the company’s revenue will be $9.19M in the next fiscal year. The high estimate is $29.26M and the low estimate is $2.78M.
